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ABSTRACT
Objectives Several physiological abnormalities that 
develop during COVID-19 are associated with increased 
mortality. In the present study, we aimed to develop a 
clinical risk score to predict the in- hospital mortality in 
COVID-19 patients, based on a set of variables available 
soon after the hospitalisation triage.
Setting Retrospective cohort study of 516 patients 
consecutively admitted for COVID-19 to two Italian tertiary 
hospitals located in Northern and Central Italy were 
collected from 22 February 2020 (date of first admission) 
to 10 April 2020.
Participants Consecutive patients≥18 years admitted for 
COVID-19.
Main outcome measures Simple clinical and laboratory 
findings readily available after triage were compared 
by patients’ survival status (‘dead’ vs ‘alive’), with the 
objective of identifying baseline variables associated with 
mortality. These were used to build a COVID-19 in- hospital 
mortality risk score (COVID- 19MRS).
Results Mean age was 67±13 years (mean±SD), and 
66.9% were male. Using Cox regression analysis, tertiles 
of increasing age (≥75, upper vs <62 years, lower: HR 
7.92; p<0.001) and number of chronic diseases (≥4 vs 
0–1: HR 2.09; p=0.007), respiratory rate (HR 1.04 per unit 
increase; p=0.001), PaO
2/FiO2 (HR 0.995 per unit increase; 
p<0.001), serum creatinine (HR 1.34 per unit increase; 
p<0.001) and platelet count (HR 0.995 per unit increase; 
p=0.001) were predictors of mortality. All six predictors 
were used to build the COVID- 19MRS (Area Under the 
Curve 0.90, 95% CI 0.87 to 0.93), which proved to be 
highly accurate in stratifying patients at low, intermediate 
and high risk of in- hospital death (p<0.001).
Conclusions The COVID- 19MRS is a rapid, operator- 
independent and inexpensive clinical tool that objectively 
predicts mortality in patients with COVID-19. The score 
could be helpful from triage to guide earlier assignment of 
COVID-19 patients to the most appropriate level of care.
INTRODUCTION
The first human cases of SARS- CoV-2 were 
reported in Wuhan, Hubei Province, China 
in January 20201 2; subsequently, it spread 
worldwide, officially being defined as a 
pandemic by WHO on 11 March 2020.3–5 Italy 
was the first country outside Asia to be heavily 
affected by the virus, with a total of 189 973 
confirmed cases as of 23 April 2020. The 
Lombardy Region had the highest burden of 
mortality and strain on its healthcare system.6 
However, a substantial reorganisation of 
healthcare facilities was necessary in all 
Italian regions to cope with the widespread 
and rapid increase in COVID-19 patient flow 
to emergency departments.
Prompt referral to the appropriate care 
setting (ie, low vs intermediate or high inten-
sity) is of crucial importance to improve 
outcomes and healthcare resource utilisa-
tion.7–9 Given the high number of patients 
to be triaged during this emergency and the 
relative shortage of hospital beds, the avail-
ability of a disease- specific mortality risk score 
since initial triage might have been useful in 
identifying the appropriate level of care and 
reducing delay. However, there is a lack of 
reliable prognostic prediction models and, 
at present, no tool for the early stratification 
of mortality risk has been fully identified.10 
A recent systematic review of prediction 
models concluded that the performance 
Strengths and limitations of the study
 ► Risk assessment tools readily available since the 
triage phase of COVID-19 are lacking.
 ► Age, previous chronic diseases, respiratory rate, 
PaO2/FiO2, creatinine and platelet count were pre-
dictors of risk of in- hospital death.
 ► All six predictors were used to build a novel 
COVID-19 clinical risk score that proved to be highly 
accurate in stratifying patients at low, intermediate 
and high risk of death.
 ► Retrospective design; novel score to be validated in 
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of prognostic estimates for COVID-19 may be overopti-
mistic and misleading, because of the high risk of bias 
in patient selection, unclear outcome definition and 
length of follow- up.10 Recently, clinical scores to predict 
the occurrence of critical illness and/or fatal outcome 
during COVID-19 were developed in a cohort of Chinese 
patients belonging to more than 500 centres throughout 
the country.11 12 However, these were developed in a 
specific region which could potentially limit the general-
isability of the risk score to other areas of the world.
Therefore, the aim of the present study was to develop 
a novel COVID-19 in- hospital mortality risk score (here-
after referred to as COVID- 19MRS), based on data 
rapidly obtainable soon after hospital admission. To 
this end, we analysed a consecutive series of COVID-19 
patients admitted to two tertiary care hospitals located in 
Northern and Central Italy.
METHODS
Study design
In this cohort study, we retrospectively reviewed the 
clinical history, laboratory and instrumental variables 
of all patients aged ≥18 years diagnosed with COVID-
19,13 admitted to two Italian tertiary hospitals located 
in Northern and Central Italy (Poliambulanza Hospital, 
Brescia; and Careggi University Hospital, Florence) from 
22 February 2020 (date of first admission in Brescia) to 
10 April 2020, in order to identify a set of early predic-
tors of mortality and build a mortality risk stratification 
score. The overall capacity of the two hospitals is about 
1800 beds. The number of beds dedicated to COVID-19 
patients progressively increased with the diffusion of the 
epidemic to a peak capacity of 655 (228/1200 in Careggi 
University Hospital and 427/600 in Poliambulanza 
Hospital; overall, 110 high- intensity care beds at peak).
Study population data source
A wide range of variables assessed on hospital admis-
sion were collected for each patient from electronic 
charts: these included demographics, number of drugs 
prescribed prior to admission, cardiovascular (CV) risk 
factors (eg, history of cigarette smoking, hypertension 
and diabetes), as well as data on previous chronic comor-
bidities (eg, CV and pulmonary diseases, cancer, depres-
sion and dementia). Functional status 2 weeks prior to 
hospitalisation was also assessed using the Barthel Index, 
in which lower values correspond to poorer function.14 
Arterial blood gases, white blood cell count, lymphocyte 
and platelet (PLT) counts, alanine aminotransferase 
and aspartate aminotransferase, creatinine, creatine 
phosphokinase, lactate dehydrogenase (LDH) and 
high- sensitivity C reactive protein (CRP) were collected 
in all patients. Chest X- ray was also collected whenever 
deemed clinically indicated. Reading and interpretation 
of the main chest X- ray features was performed according 
to radiology guidelines.15 Information on respiratory 
support and drugs prescribed during hospital stay were 
recorded. Six medical doctors (CF, MV, MC, FC, GC and 
FM) selectively extracted all variables from electronic 
charts and transferred them into a unique database and 
independently reviewed them for their consistency. Data 
were last updated on 10 April 2020.
In keeping with statements by the Italian Regulatory 
Authorities (https://www. garanteprivacy. it/ web/ guest/ 
home/ docweb/-/ docweb- display/ docweb/ 5805552), 
Ethical Committees of both hospitals (Comitato Etico 
Area Vasta Centro, Careggi University Hospital, Flor-
ence and Comitato Etico Fondazione Poliambulanza 
Hospital, Brescia, Italy) approved data collection and 
granted a waiver of informed consent from study partici-
pants. Patients’ identity was anonymised, and information 
protected by password.
Study outcome
Definition of an in- hospital all- cause mortality risk score 
based on simple, readily available clinical and laboratory 
findings.
Patient and public involvement
Patients or the public were not involved in the design or 
conduct of our research, partially due to its retrospective 
nature. Public Health Authorities will be involved in the 
upcoming, large- scale validation of the newly presented 
score.
Statistical analysis and mortality risk score derivation
Continuous variables were reported as mean±SD or as 
median with IQR, respectively, for normal and non- 
normal distributions, whereas categorical variables were 
presented as counts and percentages. All variables were 
compared by survival status (‘dead’ vs ‘alive’) and patients 
still hospitalised at study closure were considered alive 
together with those who had been discharged during 
the study period. For continuous variables, comparisons 
were performed using t- test, analysis of variance or non- 
parametric tests, as appropriate. Categorical variables 
were compared with χ2 test, or Fisher’s exact test when 
any expected cell count was less than 5.
In accordance with the aim of the study, only data 
obtained shortly after initial triage were taken into 
account to build the mortality risk score. Cox multivariate 
regression analyses (with backward stepwise elimination) 
were calculated to identify baseline characteristics inde-
pendently associated with the outcome, with inclusion of 
variables (p<0.10 by univariate analysis) which were avail-
able for all patients. A two- sided p<0.05 was considered 
statistically significant.
All continuous variables which were significantly associ-
ated with mortality by multivariate analysis were divided 
into tertiles and each of them was then scored from 1 to 3 
to quantify the increasing mortality risk. Values obtained 
were then summed up to produce the mortality risk score 
whose predictive accuracy was tested using receiver oper-
ating characteristic (ROC) analysis. The mortality risk 
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low- risk, intermediate- risk and high- risk categories, and 
assessed using Cox multivariate analysis. The Kaplan- 
Meier estimation method was computed to assess the 
probability of survival in patients in the different risk 
groups (low, intermediate and high) and compared using 
the log- rank test.
Analyses were performed using the SPSS V.26.0 statis-
tical software package for Macintosh.
RESULTS
Regional trend and clinical characteristics on hospital 
admission
During the study period, 516 consecutive patients (301 in 
Brescia and 215 in Florence) diagnosed with COVID-19 
were included in the study (table 1). According to date 
of admission, Brescia hospital anticipated both the first 
case (February 22 vs 25) and the peak of admissions by an 
average of 3 days, with a remarkably higher total and peak 
burden of admissions.
As of April 10, 314 (61%) patients had been discharged 
from hospital (273 (87%) at home and 41 (13%) to 
postacute facilities), 82 (16%) were still hospitalised, 
while 120 (23.2%) had died. Notably, no death occurred 
on the day of admission.
The mean age was 67±13 years (range 21–95) and 
345 (66.9%) patients were male. Demographic and 
clinical characteristics of non- survivors and survivors 
are reported in table 1. Non- survivors were significantly 
Table 1 Demographic and clinical characteristics on hospital admission
   Overall (N=516)    Dead (N=120)   Alive (N=396)   P value
Demographic characteristics
  Age, years, mean±SD 67±13 79±8 64±12 <0.001
Age (tertiles)
  <62, N (%) 177 (34.3) 7 (5.8) 170 (42.9)
  62–74, N (%) 171 (33.1) 27 (22.5) 144 (36.4)
  ≥75, N (%) 168 (32.6) 86 (71.7) 82 (20.7)
Hospital stay, median (IQR) 9 (5–14) 6 (3–10) 10 (6–15) <0.001
Gender (male), N (%) 345 (66.9) 85 (70.8) 260 (65.7) 0.321
Smoking history, N (%) 112 (21.7) 26 (21.7) 86 (21.7) 0.999
Hypertension, N (%) 182 (35.3) 65 (55.6) 117 (29.6) <0.001
Diabetes mellitus, N (%) 161 (31.4) 51 (43.6) 110 (27.8) <0.001
CV disease, N (%) 146 (28.5) 57 (47.9) 89 (22.6) <0.001
Previous stroke/TIA, N (%) 25 (4.9) 11 (9.1) 14 (3.5) 0.011
COPD, N (%) 36 (7.0) 12 (10) 24 (6.1) 0.120
Cancer, N (%) 50 (9.7) 23 (19.2) 27 (6.8) <0.001
Depression, N (%) 52 (20.1) 20 (17.1) 32 (8.1) 0.005
Dementia, N (%) 18 (3.4) 12 (10.0) 6 (1.5) <0.001
Comorbidities* mean±SD 2.1±1.7 3.2±1.9 1.8±1.6 <0.001
  >3, N (%) 179 (34.7) 68 (58.1) 111 (28.2) <0.001
Barthel Index, mean±SD 85±28 77±27 94±1 3 <0.001
ACE- i/ARBs, N (%) 144 (27.9) 35 (29.2) 109 (27.5) 0.725
Drugs, N (%) 3.4±3.3 5.6±3.5 2.7±2.7 <0.001
Signs and symptoms
  Fever, N (%) 456 (89.1) 102 (87.2) 354 (89.5) 0.457
  Cough, N (%) 293 (57.3) 57 (48.5) 236 (59.8) 0.032
  Dyspnoea, N (%) 250 (48.9) 59 (50.4) 191 (48.5) 0.711
  Respiratory rate, mean±SD 23±7 26±7 21±6 <0.001
  Insomnia, N (%) 68 (13.2) 18 (15) 50 (12.6) 0.004
  Diarrhoea, N (%) 47 (9.2) 10 (8.3) 37 (9.4) 0.782
  Syncope, N (%) 27 (5.2) 11 (9.2) 16 (4.1) 0.023
  Altered mental status, N (%) 24 (4.7) 12 (10.0) 12 (3.0) <0.001
*Comorbidities are a composite variable including from hypertension to dementia. Percentages in brackets are calculated for numbers in 
columns for all dichotomous variables.
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older (79±8 vs 64±12 years, p<0.001). Indeed, in- hospital 
fatality rate sharply increased with age and was more than 
five times higher in individuals aged ≥75 years (51.2% 
vs <75 years 9.8%; p<0.001). Conversely, prognosis was 
similar for both genders. The median hospital stay was 9 
(IQR 5–14) days, significantly longer in survivors. Non- 
survivors also presented with a higher prevalence of CV 
risk factors, a greater burden of chronic comorbidities, 
and were more functionally impaired as indicated by 
a lower Barthel Index Score (table 1). Previous use of 
ACE inhibitors or angiotensin receptor blockers was 
similar in both groups while, in accordance with their 
higher burden of comorbidities, non- survivors reported 
a greater number of drugs chronically assumed prior 
to hospitalisation. The majority of patients presented 
with fever (89.1%) and/or cough (57.3%). Of note, 
non- survivors reported cough less frequently (48.5% vs 
59.8%; p=0.032), but had a significantly higher preva-
lence of insomnia, syncope or altered mental status. 
While the prevalence of dyspnoea was similar in both 
groups (overall, 48.9%), respiratory rate on admission 
was higher in non- survivors than in survivors (26±7 vs 
21±6 breaths/min; p<0.001).
Laboratory and imaging findings
Nasopharyngeal swab was positive in 499 (97%) patients. 
In the remaining patients, initially suspected diagnosis 
was confirmed by subsequent swabs, sputum or bron-
choalveolar lavage. Laboratory findings are presented 
in table 2. In the entire population, median PaO2/FiO2 
ratio was 269 (IQR 217–319), and values<200 were signifi-
cantly associated with the probability of death. Lympho-
cytopaenia was present in 61% of the population, more 
frequently among non- survivors than survivors (71% vs 
58%; p=0.011), who also had lower PLT count and higher 
serum creatinine. CRP and LDH were increased in both 
groups and higher in non- survivors. Chest X- ray was 
abnormal in >95% of cases, with a trend towards a higher 
prevalence of interstitial or mixed (both interstitial and 
consolidation) patterns in deceased patients.
Medical management and clinical outcomes
Non- survivors required non- invasive (continuous posi-
tive airway pressure and biphasic positive airway pressure 
modes) or invasive ventilation more frequently than survi-
vors (table 3). While antibiotics were prescribed more 
frequently to non- survivors, heparin, hydroxychloroquine, 
Table 2 Laboratory and imaging findings on admission
  Overall (N=516)   Dead (N=120)   Alive (N=396)   P value
Laboratory findings
  PaO2/FiO2, median (IQR) 269 (217–319) 226 (169–271) 281 (232–335) <0.001
   <200, N (%) 101 (19.6) 42 (35.0) 59 (15.0) <0.001
   ≥200, N (%) 415 (80.4) 78 (65.0) 337 (85.1)
  Haematocrit, % median (IQR) 41 (38–44) 39 (35–43) 42 (39–44.75) <0.001
  Haemoglobin, g/L median (IQR) 130 (117–143) 129 (117–141) 133 (122–143) 0.203
  WBC, (×109/L) median (IQR) 6.31 (5–9) 7.11 (5–10.23) 6 (4.98–8.47) 0.009
  Lymphocytes, (×109/L) median (IQR) 0.90 (0.70–1.24) 0.77 (0.70–1.07) 0.90 (0.70–1.24) <0.001
  Lymphocytopaenia, N (%) 316 (61) 85 (71) 231 (58) 0.011
  Platelets, (×109/L) median (IQR) 182 (142–234) 156 (117–218) 187 (152–238) 0.001
  ALT, U/L median (IQR) 31 (19–51) 26 (16–42) 32 (19–58) 0.004
  AST, U/L median (IQR) 46 (30–69) 50 (35–71) 45 (28–69) 0.181
  Serum creatinine, mg/dL median (IQR) 0.94 (0.79–1.22) 1.23 (0.92–1.91) 0.90 (0.79–1.13) <0.001
  CPK, U/L median (IQR) 110 (64–228) 130 (60–208) 108 (64–208) 0.085
  LDH, U/L median (IQR) 351 (268–480) 473 (338–610) 335 (266–437) <0.001
  CRP, mg/L median (IQR) 94 (44.3–161.8) 138 (85–188) 77 (37–152) <0.001
Imaging N=486 N=114 N=372
Chest X- ray
  Negative, N (%) 20 (4.1) 2 (1.8) 18 (4.8) 0.053
  Consolidation, N (%) 67 (13.8) 12 (10.5) 55 (14.8)
  Interstitial, N (%) 346 (71.2) 81 (71.1) 265 (71.2)
  Mixed, N (%) 53 (10.9) 19 (16.7) 34 (9.1)
Percentages in round brackets are calculated for numbers in columns for all dichotomous variables
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; CRP, C reactive protein; LDH, lactate 
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antiviral agents (combination of lopinavir/ritonavir) 
and monoclonal antibodies (mAbs, tocilizumab) were 
prescribed more frequently to survivors. In contrast, 
corticosteroid therapy was adopted in similar proportions 
in the two groups. Patients receiving mAbs were younger 
(65±9 vs 68±14 years, p<0.01) and had lower serum creat-
inine (0.9±0.3 vs 1.2±0.9 mg/dL, p=0.024).
Predictors of mortality and development of the mortality risk 
score
At Cox multivariate regression analysis (table 4), age, 
number of chronic comorbidities, respiratory rate and 
serum creatinine emerged as positive predictors, while 
PaO2/FiO2 ratio and PLT count were negative predictors 
of death. Online supplemental table 1 summarises all 
candidate variables that were excluded by stepwise back-
ward deletion. Interestingly, preadmission functional 
status as assessed by Barthel Index and the number of 
drugs previously assumed were excluded from the model.
Variables included in the model (table 4) were used 
to calculate the mortality risk score intended for rapid 
patient’s risk assessment on hospital admission. In this 
regard, age, number of comorbidities, respiratory rate, 
PaO2/FiO2, serum creatinine and PLT count reclassified 
into tertiles were used to build the mortality risk score 
with identification of three risk strata as reported in 
table 5. ROC analysis performed on the clinical risk score 
yielded an Area Under the Curve (AUC) of 0.90 (online 
supplemental figure 1, 95% CI 0.87 to 0.93). Kaplan- 
Meier survival analysis developed using the tertiles of the 
clinical score showed an excellent stratification of risk 
(figure 1; intermediate- risk vs low- risk HR: 4.134, 95% CI 
1.725 to 9.905; high- risk vs low- risk HR: 22.173, 95% CI 
9.681 to 50.783, p<0.001). A cut- off score of ≤8 identified 
a subset of 63 (12.2%) patients without fatalities during 
the study period, which therefore may be defined as ‘at 
very low risk’.
DISCUSSION
In this study, we developed the COVID- 19MRS that 
was shown to be able to stratify the risk of in- hospital 
death in COVID-19 patients since their admission. This 
score includes a composite of six objective, operator- 
independent variables (age, number of chronic comor-
bidities, respiratory rate, PaO2/FiO2, serum creatinine 
and platelet count) usually available within a couple of 
hours after hospitalisation. The score identified three 
categories at increasing risk of death with a high level of 
accuracy. The scoring process suggests that, while low- 
risk patients may be assigned safely to low- intensity care, 
higher intensity wards should be alerted during triage for 
the intermediate- risk and high- risk patients. Moreover, 
the score seems to allow for the identification of about 
Table 3 Treatment strategies
Overall (N=516) Dead (N=120) Alive (N=396) P value
Respiratory support
  None, N (%) 57 (11.0) 2 (1.7) 55 (13.9) <0.001
  Oxygen, N (%) 334 (64.7) 78 (65.0) 256 (65.1)
  Non- invasive ventilation, N (%) 65 (12.6) 23 (19.2) 42 (10.6)
  Invasive ventilation, N (%) 60 (11.6) 17 (14.2) 43 (10.9)
Drugs
  Antibiotics, N (%) 407 (78.9) 106 (88.3) 301 (76.0) 0.003
  Heparin, N (%) 299 (57.9) 57 (47.5) 242 (61.1) 0.008
  Hydroxychloroquine, N (%) 268 (51.9) 43 (35.8) 225 (56.8) <0.001
  Lopinavir/ritonavir, N (%) 247 (50.7) 39 (32.5) 208 (52.5) <0.001
  Corticosteroids, N (%) 176 (34.1) 45 (37.5) 131 (33.1) 0.371
  Monoclonal antibodies, N (%) 57 (11.3) 3 (2.5) 54 (13.6) <0.001
Table 4 Cox multivariable regression analyses of 
determinants of in- hospital mortality
Variables HR 95.0% CI P value
Age (tertiles)
  62–74 versus <62 years 2.86 1.23 to 6.64 0.014
  ≥75 versus <62 years 7.92 3.60 to 17.43 <0.001
Number of comorbidities (tertiles)
  2–3 versus 0–1 1.85 1.11 to 3.08 0.018
  ≥4 versus 0–1 2.09 1.23 to 3.55 0.007
Respiratory rate (breaths/
min), for unit increase
1.04 1.02 to 1.07 0.001
PaO2/FiO2, for unit 
increase
0.995 0.992 to 0.997 <0.001
Creatinine (mg/dL), for unit 
increase
1.34 1.18 to 1.51 <0.001
Platelets (109/L), for unit 
increase
0.995 0.992 to 0.998 0.001
History of cardiovascular disease, hypertension, diabetes, 
depression, dementia and cancer were included into 
‘comorbidities’. Variables excluded (p>0.10) from both models: 




















pen: first published as 10.1136/bm






6 Fumagalli C, et al. BMJ Open 2020;10:e040729. doi:10.1136/bmjopen-2020-040729
Open access 
10%–15% of ‘very low- risk’ patients (score ≤8) with no 
events who, though symptomatic for proven COVID-19, 
might be immediately discharged home, with the sole 
indication to health status monitoring.
Performance of prognostic estimates for COVID-19 
is under scrutiny as thought to be over optimistic and 
misleading, because of the high risk of bias in patient 
selection.10 As a case in point, a score based on a large 
cohort of COVID-19 patients in China found that age 
was associated with greater risk of death.11 However, the 
mean age of this cohort was 49±16 years, which is 15–20 
years less than observed in most European and US studies 
published to date. Although apparently similar in terms 
of objectives, we stratified the risk of death in a consec-
utive cohort of patients who shared demographic and 
clinical characteristics similar to other European and US 
studies.3–5 We, therefore, believe that our COVID- 19MRS 
may hold potential generalisability for other countries. 
The early identification of patients at risk of clinical dete-
rioration and death is of primary importance, consid-
ering that median interval from hospital admission to the 
Intensive Care Unit (ICU) is around 3 days16. Given that 
our proposed score is predictive of mortality based on six 
inexpensive, operator- independent and rapidly obtain-
able parameters, it could help clinicians to identify high- 
risk patients with poor prognosis since the triage phase.
One in four patients in our cohort of Italian COVID-19 
cases died and age was the strongest driver of an adverse 
outcome. In fact, compared with patients younger than 62 
years of age, the risk of death was almost three and eight 
times higher in individuals 62–74 and 75+ years of age, 
respectively. Such an exponential risk growth persisted 
after adjusting for burden of comorbidities and a series of 
clinical characteristics. Such a strong association between 
older age and prognosis has been observed in previous 
studies on COVID-19 both in China and in other coun-
tries, although with a less rapid increase in age- specific 
risk.17 This difference could be attributed to the lower 
median age reported in those studies and to the fact 
that we explored a wider age range (21–95 years), with 
one- third of our population above the age of 75.17 18 In 
COVID-19, age has been associated with variable degrees 
of increasing risk of admissions to ICU, onset of acute 
respiratory distress syndrome, myocardial damage and 
fatal outcome.16 19–22 This observation also holds true 
for previous epidemic or pandemic outbreaks, such as 
SARS and Middle East respiratory syndrome where, as in 
COVID-19, the respiratory system is both the entry route 
and the main target of viral infection.23 24 We could argue 
that lung senescence, resulting in decreased elasticity, 
increased end- expiratory lung volume and disrupted 
alveolar integrity,25 together with kidney senescence,26 












(sum of individual 
variable scores)
<62 1 ≤1 1 ≤20 1 >300 1 <0.83 1 >212 1 Low ≤10
62–74 2 2–3 2 21–24 2 236–299 2 0.83–1.12 2 156–211 2 Intermediate=11–13
≥75 3 ≥4 3 ≥25 3 <236 3 ≥1.13 3 <156 3 High risk ≥14
Categories represent the tertile distribution of each variable.
Figure 1 Kaplan- Meier analysis of overall survival of patients diagnosed with COVID-19 according to three risk categories. 
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may predispose per se to SARS- CoV-2- related acute respi-
ratory and renal failure even in otherwise relatively robust 
elderly individuals. This hypothesis is consistent with the 
observation that age and three functional indicators of 
target organs (respiratory rate, PaO2/FiO2 and serum 
creatinine) emerged as independent predictors of in- hos-
pital mortality, after adjusting for comorbidities.
The observation of the highly negative impact of age 
suggests that in the absence of specifically effective drug 
therapy and vaccination,27 social isolation and the preven-
tion of infecting contacts are key issues particularly rele-
vant in individuals aged 70–75 years and over. These data 
may represent a call to action for health authorities, in 
order to update management policies in the community 
in general and in nursing homes in particular, where in 
fact the highest mortality rates occurred in Italy and in 
other countries.28
While a low PLT count was frequently observed in non- 
survivor COVID-19 patients,16 19 22 29 in our cohort, lower 
values were directly associated with adverse outcome, 
suggesting a possible role of COVID-19- related coagulop-
athy in determining a poor outcome.30 31
Present therapeutic recommendations on COVID-19 
have a limited level of evidence,32 and have evolved 
during progression of the pandemic wave. Most of our 
patients received oxygen or mechanical ventilation 
support and antibiotics; conversely one in two patients 
were treated by antiviral and/or anti- inflammatory drugs. 
Given the nature of our study, we are unable to draw any 
firm conclusions regarding treatment efficacy, as specific 
analyses would be required, which were beyond the scope 
of the present work.
Some limitations of our study have to be acknowledged. 
First, the retrospective and observational nature of our 
analysis does not allow us to draw any firm conclusions 
about therapeutic strategies. Second, some laboratory 
parameters, which proved to be of prognostic relevance 
in other studies,19 22 were not collected for all individuals 
in our sample, possibly due to the different degrees of 
severity of patients (ie, very mildly affected vs critically ill 
patients at presentation). Therefore, we cannot rule out 
that variables excluded from the scoring system would 
have had a significant impact on mortality prediction. 
However, consistent with our purpose, we considered 
variables only available soon after admission. Third, 
since nasopharyngeal swabs were our key criterion for 
SARS- CoV-2 detection, we did not assess viremia, while 
the correlation of viral load with disease severity is still 
a matter of debate. Moreover, case ascertainment meth-
odological bias, which may impact on patient selection 
and outcome, cannot be excluded as partial explanation 
for the findings observed. Indeed, the vast majority of 
patients included in the present analysis had a positive 
RT- PCR on first testing and only in a minority of cases 
was sputum or bronchoalveolar lavage needed to confirm 
the infection. Fourth, 82 (15.9%) out of 516 patients were 
still in- hospital at the time of closure of follow- up. Never-
theless, after excluding these patients from our analysis, 
results were fully confirmed, with a 0.90 AUC of the 
predictive score (data not shown). Finally, we do not have 
information regarding the time span between symptom 
onset and admission, which might have had an impact on 
either clinical or laboratory parameters that we sampled 
on hospital admission.
In conclusion, we developed a scoring system (COVID- 
19MRS) that objectively and accurately predicts in- hos-
pital mortality COVID-19 patients. This score, simply 
based on age, number of chronic comorbidities, respira-
tory rate, PaO2/FiO2, serum creatinine and platelet count, 
is a rapid and inexpensive clinical tool, which could be 
helpful for earlier identification of in- hospital mortality 
risk and, hence, assignment to the appropriate level of 
care and treatment of COVID-19 patients. Studies in clin-
ical series different from ours are needed to validate the 
present scoring system.
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